Hemi-central retinal vein occlusion as a rare manifestation of the hypercoagulable state in COVID-19.
BMJ Case Rep
; 14(11)2021 Nov 01.
Article
in English
| MEDLINE | ID: covidwho-1495132
ABSTRACT
To date, COVID-19 has no definite effective targeted therapy, and management is primarily supportive. Central retinal vein occlusion (CRVO) is frequently caused by systemic risk factors posing hypercoagulable states. In April 2020, a female patient with a history of hypertension, diabetes mellitus and chronic kidney disease presented with 2 days of loose, watery stools, nasal congestion and severe lethargy. The patient denied dyspnoea or fever. A week after the initial symptoms, the patient reported decreased vision from the left eye. Dilated funduscopy and fluorescein angiography suggested hemi-CRVO. The patient refused intravitreal antivascular endothelial growth factor agents because of non-severe visual loss. Testing was positive for COVID-19 IgG antibodies; reverse transcription PCR was not available. Vision improved within 3 weeks of presentation. We recommend that clinicians keep a high suspicion for acute onset of thrombotic events in patients with COVID-19 and thrombotic predisposing risk factors.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Retinal Vein Occlusion
/
COVID-19
Type of study:
Case report
/
Diagnostic study
/
Prognostic study
Limits:
Female
/
Humans
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Bcr-2021-246428
Similar
MEDLINE
...
LILACS
LIS